Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

European Journal of Cancer

Volumn 49, Issue 18, 2013, Pages 3831-3838

  Gonzalez Martin, Antonio ^a   Gladieff, Laurence ^b   Tholander, Bengt ^c   Stroyakovsky, Daniel ^d   Gore, Martin ^e   Scambia, Giovanni ^f   Kovalenko, Nadezhda ^g   Oaknin, Ana ^h   Ronco, Julian Perez ⁱ   Freudensprung, Ulrich ⁱ   Pignata, Sandro ^j  

^a MD ANDERSON CANCER CENTER   (Spain)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d Moscow Oncological Hospital No 62   (Russian Federation)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f CATHOLIC UNIVERSITY   (Italy)

^g Regional Clinical Oncology Dispensary   (Russian Federation)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

Angiogenesis; Bevacizumab; Front line; Ovarian cancer; Weekly paclitaxel

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER STAGING; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FISTULA; HUMAN; HYPERTENSION; LEUKOENCEPHALOPATHY; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVERSIBLE POSTERIOR LEUCOENCEPHALOPATHY SYNDROME; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANGIOGENESIS; BEVACIZUMAB; FRONT-LINE; OVARIAN CANCER; WEEKLY PACLITAXEL;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; PACLITAXEL; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888007187     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.002     Document Type: Article

References (19)

1. A. du Bois, H.J. Lück, and W. Meier Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
2. A. du Bois, J. Herrstedt, and A.C. Hardy-Bessard Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer J Clin Oncol 28 2010 4162 4169
3. A. du Bois, B. Weber, and J. Rochon Arbeitsgemeinschaft Gynaekologische Onkologie; Ovarian Cancer Study Group; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J Clin Oncol 24 2006 1127 1135
4. G. Bolis, G. Scarfone, and F. Raspagliesi Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer: a multicenter, randomized study Eur J Cancer 46 2010 2905 2912
5. J. Pfisterer, B. Weber, and A. Reuss AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 2006 1036 1045
6. P.A. Vasey, G.C. Jayson, and A. Gordon Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
7. S. De Placido, G. Scambia, and G. Di Vagno Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study J Clin Oncol 22 2004 2635 2642
8. D.K. Armstrong, B. Bundy, and L. Wenzel Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
9. N. Katsumata, M. Yasuda, and F. Takahashi Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
10. R.A. Burger, M.F. Brady, and M.A. Bookman Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
11. T.J. Perren, A.M. Swart, and J. Pfisterer ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
12. D. Belotti, V. Vergani, and T. Drudis The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1996 1843 1849
13. K.D. Miller, C.J. Sweeney, and G.W. Sledge Jr. Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 2001 1195 1206
14. H. Jiang, W. Tao, M. Zhang, S. Pan, J.R. Kanwar, and X. Sun Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice Cancer Invest 28 2010 74 84
15. R. Brookmeyer, and J. Crowley A confidence interval for the median survival time Biometrics 38 1982 29 41
16. S. Pignata, G. Scambia, and G. Ferrandina Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial J Clin Oncol 29 2011 3628 3635
17. M.E. Van der Burg, J.T. Janssen, and P.B. Ottevanger Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC) J Clin Oncol 27 15s Suppl. 2009 Abstr. 5538
18. S. Pignata, G. Scambia, and R. Lauria A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) - European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial J Clin Oncol 31 Suppl. 2013 Abstr. LBA5501
19. Roche data on file, 2010: Clinical Study Report - BO17707 (ICON7). A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer. Report No. 1035868, November 2010.